Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Cabometyx
Pharma
ESMO: Exelixis faces uphill battle with kidney cancer triplet
The triplet combo of Cabometyx, Opdivo and Yervoy showed a tumor progression advantage over a weak comparator, making it a dubious win.
Angus Liu
Sep 12, 2022 10:30am
Exelixis trots out triplet kidney cancer win
Jul 11, 2022 10:34am
Exelixis axes Cabometyx-Tecentriq combo in liver cancer
Mar 15, 2022 11:05am
Exelixis touts early prostate cancer data for Cabometyx combo
Sep 17, 2021 6:05pm
BMS touts 5-year kidney cancer win in heated fight with Keytruda
Sep 16, 2021 2:30am
Cabometyx-Tecentriq combo surprisingly fails in liver cancer
Jun 28, 2021 10:22am
